Harmony Biosciences Q1 revenue $154.6M (+30% YoY); reaffirms FY2024 guidance $700-720M

Harmony Biosciences Holdings, Inc.

2024-Q1 EPS reported $0.67 revenue$154,615,000

Q1 net revenue $154.6M (+30% YoY); GAAP EPS $0.67, adjusted EPS $0.88.
Reaffirmed FY 2024 net revenue guidance of $700-720M.
Pipeline: sNDA for pitolisant in IH planned H2 2024; pediatric narcolepsy PDUFA June 21, 2024.
Licensed TPM-1116 (orexin-2 agonist) for narcolepsy; IND expected mid-2025.
Acquired Epygenix for rare epilepsy; clemizole Dravet/LGS pivotal trial topline 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Harmony Biosciences Holdings, Inc. reported Q1 2024 results: revenue WAKIX Net Revenue of $154.6 Million, net income GAAP net income for the quarter ended March 31, 2024, was $38.3 million, EPS $0.67 per diluted share. Guidance reaffirmed.

Period: Q1 2024
Revenue: WAKIX Net Revenue of $154.6 Million
Net income: GAAP net income for the quarter ended March 31, 2024, was $38.3 million
EPS: $0.67 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

ADVANCES PITOLISANT FRANCHISE TO EXTEND REVENUE POTENTIAL BEYOND 2040; STRENGHTENS SLEEP/WAKE LEADERSHIP AND DIVERSIFIES INTO RARE EPILEPSY WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 On Track Toward

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-006200

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.